Compare Amphastar Pharmaceuticals Inc (AMPH) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Boston Beer Company Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Boston Beer Company Inc trades at $176.79 (market cap $1.84B). The key difference: Boston Beer Company Inc is far larger — about 2.2× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | SAM | |
|---|---|---|
Market Cap | $826.08M | $1.84B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $260.05 |
52-Week Low | $16.87 | $161.08 |
Enterprise Value | $1.22B | $1.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SAM trades at $176.79, up 1.1% on the day, amid a bearish technical signal but with a consensus analyst price target of $222.67 suggesting upside. Recent earnings show volatility with a Q1 2026 miss, while full-year 2025 net income improved to $108.47M. Cash flow remains positive, but 2026 revenue and profit projections indicate challenges. The company is investing in brand innovation and Beyond Beer expansion to drive growth.
The outlook is mixed; valuation ratios appear reasonable, and strategic initiatives support long-term potential, but near-term volume pressure and negative 2026 profit forecasts pose risks. Investor sentiment is cautious, with most analysts rating Hold. Key catalysts include execution on cost savings and brand momentum against a competitive backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
